Trevi Therapeutics, Inc.

NasdaqGM TRVI

Trevi Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024

Trevi Therapeutics, Inc. Free Cash Flow Per Share is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Trevi Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.62, a 60.85% change year over year.
Trevi Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -1.59, a -8.18% change year over year.
Trevi Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -1.47, a -20.31% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqGM: TRVI

Trevi Therapeutics, Inc.

CEO	Ms. Jennifer L. Good
IPO Date	May 7, 2019
Location	United States
Headquarters	195 Church Street
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Personal Care

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Key trends

Past 5 years